Menu

Study: Microglia Tied to Weight Gain in Mice

Just by activating these immune cells in the brain, scientists could make mice eat more and burn fewer calories.

Jul 5, 2017
Aggie Mika

A slice of the mediobasal hypothalamus, taken from a mouse fed a high-fat diet, depicts accumulating microglia (green) along with Agouti-related protein neurons (AgRP; red). AgRP neurons are important regulators of food consumption and body composition.

THE SUNEIL KOLIWAD LAB

   Microglia—the brain’s own macrophages—can prompt excess eating and subsequent weight gain in mice fed high-fat diets, according to a study published today (July 5) in Cell Metabolism. The researchers demonstrate that an appetite-promoting inflammatory cascade driven by these immune cells occurs within the mediobasal region of the hypothalamus, a structure that, according to a news release, “contains key groups of neurons that regulate food intake and energy expenditure.”

Prior studies have demonstrated that when mice are fed a diet high in saturated fat, they consume more while expending fewer calories, leading them to gain weight, the news release states. Additionally, previous work in both obese mice and humans has also shown that microglia within the hypothalamus increase following high-fat feeding, prompting inflammation, the authors write in their report.

In the current study, the researchers examined whether microglial activity in the mediobasal hypothalamus had anything to do with the increased food consumption and weight gain observed in mice consuming diets high in fat.

First, they used a drug to wipe out microglia in this region brain and found that microglia-lacking, high-fat consuming mice gained less weight than their non-drugged, high-fat counterparts. They then genetically manipulated mice so that their microglia weren’t capable of mounting an inflammatory response, and these mice also ate less and gained less weight than normal mice on the high-fat diets.

Ongoing clinical trials testing the effects of a similar drug called PLX3977 in patients with certain cancers and arthritis may be able to shed some light on whether pharmacologically targeting microglia can impact weight, notes senior author Suneil Koliwad of the University of California, San Francisco, in the news release.

To find out if microglial activity alone could trigger overeating and weight gain in mice on a normal low-fat diet, the scientists induced microglial inflammation in the rodents’ brains. Indeed, despite eating diets lower in fat, hypothalamic inflammation drove these mice to burn fewer calories, eat more, and gain more weight than control mice on normal diets.

“From these experiments we can confidently say that the inflammatory activation of microglia is not only necessary for high-fat diets to induce obesity, but also sufficient on its own to drive the hypothalamus to alter its regulation of energy balance, leading to excess weight gain,” says co-senior author Joshua Thaler of the University of Washington, in the news release.

When high-fat foods were scarce, microglia could have evolved to amplify appetite to increase consumption of energy-rich meals, adds Koliwad. But this adaptation may no longer be advantageous. “In our modern world, when people constantly overeat rich, high-fat foods, chronic microglial activation could produce a more permanent stimulation of neural circuits that further increase high-fat food intake, leading to the development of a vicious cycle.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.